A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
18 Years - 130 Years
Endpoint Classification: -
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Verified 01 May 2023 by AstraZeneca
No locations available
|Experimental: Capivasertib monotherapy|
Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.